Basis: FMP quote market capitalization / revenue from four consecutive issuer fiscal quarters. Source: stored company filings and market data; unavailable inputs remain N/A.
The P/S ratio is N/A as of 2026-10-06T22:21:19.122Z.
Calculation as of: 2026-10-06T22:21:19.122Z.
Quote observation: 2026-10-06T20:00:00.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 003104a745df447911be4c5a9e680832c7b19445192e606e8359fbce1df4db86
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
PS RATIO
N/A
Market Cap
$1.01M
PS Ratio
10.35
TTM Avg
20733.20
3Y Avg
20733.20
5Y Avg
20733.20
Market Cap
$946332.00
PS Ratio
0.03
TTM Avg
0.09
3Y Avg
2.07
5Y Avg
14903.13
Market Cap
$901902.00
PS Ratio
N/A
TTM Avg
48450.87
3Y Avg
43764.18
5Y Avg
43764.18
| NAME | MARKET CAP | PS RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Clearmind Medicine Inc. (CMND) | $1.08M | N/A | N/A | N/A | N/A |
| Propanc Biopharma, Inc. (PPCB)vs › | $1.12M | N/A | N/A | N/A | N/A |
| Cellyan Biotechnology Co., Ltd (HKPD)vs › | $1.13M | N/A | N/A | N/A | N/A |
| Aspire Biopharma Holdings, Inc. (ASBP)vs › | $1.01M | 10.35 | 20733.20 | 20733.20 | 20733.20 |
| IM Cannabis Corp. (IMCC)vs › | $1.17M | 0.04 | 0.21 | 0.18 | 0.97 |
| Sunshine Biopharma, Inc. (SBFM)vs › | $946332.00 | 0.03 | 0.09 | 2.07 | 14903.13 |
| GlucoTrack, Inc. (GCTK)vs › | $901902.00 | N/A | 48450.87 | 43764.18 | 43764.18 |
| Bone Biologics Corporation (BBLG)vs › | $868077.00 | N/A | N/A | N/A | N/A |
| Genprex, Inc. (GNPX)vs › | $1.32M | N/A | N/A | N/A | N/A |
| Bluejay Diagnostics, Inc. (BJDX)vs › | $838843.00 | N/A | 2215.39 | 2233.86 | 2233.86 |
Trailing-12-month revenue adds these four fiscal quarters. Amounts are in USD, rounded only to whole currency units.
Reported statement amounts were converted from USD to USD using the stored FMP exchange-rate calculation.
| Fiscal period | Revenue | Source |
|---|---|---|
| Q4 FY2025Period ended 2025-10-31 | $0 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-01-20 |
| Q1 FY2026Period ended 2026-01-31 | $0 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-03-12 |
| Q2 FY2026Period ended 2026-04-30 | $0 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-06-15 |
| Q3 FY2026Period ended 2026-07-31 | $0 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-09-10 |
| TTM revenue | $0 |
The current P/S calculation cannot be reconciled from the stored quote and revenue inputs.
These references are supplied through FMP. Full filing context identifiers and dimensional metadata are unavailable in the normalized feed.
P/S Ratio
N/A
Market Cap / Trailing Twelve-Month Revenue
PS Ratio = Market Cap / Revenue (TTM)
The price-to-sales ratio compares market capitalization to trailing revenue. It is useful for valuing companies with little or no earnings.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
